Spring­Works stalled in pre-launch mode for brand com­mu­ni­ca­tions af­ter FDA de­ci­sion de­lay

Spring­Works Ther­a­peu­tics was cruis­ing along with its pre-launch mar­ket­ing plans for its rare desmoid tu­mor drug can­di­date nirogace­s­tat. Its FDA de­ci­sion date was set for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER